As an oncologic rheumatologist planning a multicenter randomized trial of checkpoint inhibitor–related immunotoxicities, what comprehensive questionnaire (including baseline demographics, clinical data, vital signs, laboratory panels, and immune‑related adverse‑event symptom checklist) should be used for patient enrollment, and where can I access the online citations for this questionnaire?

Comprehensive Questionnaire for Multicenter Checkpoint Inhibitor Immunotoxicity Studies

As an onco-rheumatologist organizing a multicenter trial on checkpoint inhibitor immunotoxicities, you should implement the standardized baseline assessment checklist from the 2016 French collaborative position paper 1, which provides the most comprehensive and practical framework for patient enrollment and longitudinal monitoring.

Baseline Patient Enrollment Questionnaire

Demographics and Clinical History

• Performance status (ECOG/Karnofsky)
• Anthropometrics: Weight, height, body mass index
• Cancer type and stage
• Prior oncologic treatments (chemotherapy, radiation, targeted therapy)
• Complete autoimmune disease history (personal and family) – critical as these patients have higher flare risk 2
• Current medications including immunosuppressants
• History of organ-specific symptoms: intestinal transit patterns, dyspnea, cough, rash, nausea, headaches, motor/sensory neuropathy, arthralgia 1
• Recent infections or fever requiring investigation before ICI initiation

Physical Examination Parameters

• Heart rate and blood pressure
• General symptoms: asthenia, appetite changes
• Pre-existing symptom severity scoring for gastrointestinal, pulmonary, dermatologic, neurologic, and musculoskeletal systems 1
• Baseline electrocardiogram 1

Laboratory Panel for Baseline and Serial Monitoring

Hematologic and Metabolic

• Complete blood count (CBC) with differential
• Comprehensive metabolic panel: sodium, potassium, bicarbonate, calcium, phosphorus, uric acid
• Renal function: creatinine with estimated GFR (MDRD or CKD-EPI formula) 1
• Glucose (fasting if possible)
• Liver function: total bilirubin, AST, ALT, GGT, alkaline phosphatase 1
• Albumin and C-reactive protein

Endocrine Baseline Assessment

• TSH and free T4 1
• Morning cortisol and ACTH (8 AM fasting) 1
• LH, FSH, estradiol/testosterone (sex-appropriate) 1

Renal-Specific Monitoring

• Morning urine protein-to-creatinine ratio (superior to dipstick for detecting low-level and tubular proteinuria) 1
• Urinary sediment analysis 1
• Monitor serum creatinine prior to every ICI dose 2

Autoimmune and Rheumatologic Screening

The evidence is mixed on universal autoantibody screening. The 2021 EULAR guidelines explicitly state there is no indication to test every patient for autoantibodies before ICI initiation 3. However, the French collaborative position recommends baseline testing 1:

• Antinuclear antibodies (ANA)
• Thyroid peroxidase antibodies (TPO Ab)
• Thyroglobulin antibodies (Tg Ab)

For symptomatic patients during treatment, perform complete rheumatologic workup 2:

• ANA, rheumatoid factor (RF), anti-CCP antibodies
• Creatine kinase (CK) to evaluate myositis
• Inflammatory markers (ESR, CRP)

Infectious Disease Screening

• QuantiFERON tuberculosis or tuberculin skin test (if prior TB exposure) 1
• HIV, hepatitis C virus, hepatitis B virus serology 1

Biobanking for Future Analysis

Plasma/serum biobanking before immunotherapy initiation is strongly recommended to retrospectively measure biomarkers of interest if toxicity develops 1. This is critical for multicenter studies investigating predictive biomarkers 4.

Imaging Requirements

• Baseline chest X-ray for pulmonary reference 1
• Thin-section chest CT with and without contrast to establish baseline for potential pneumonitis detection 1
• Standard oncologic staging imaging (chest/abdomen/pelvis CT, brain MRI as indicated)

Immune-Related Adverse Event Symptom Checklist

Organ-Specific Toxicity Monitoring (CTCAE v5.0 Grading)

Dermatologic (most common, 34-45% incidence) 5, 6, 5:

• Rash severity and body surface area involvement
• Pruritus intensity
• Vitiligo (melanoma patients – associated with response) 6

Gastrointestinal 7, 5:

• Diarrhea frequency (number of stools above baseline)
• Abdominal pain severity
• Blood in stool
• Nausea/vomiting frequency

Musculoskeletal/Rheumatologic (7.35% incidence, 23.8% of all irAEs) 2, 8:

• Joint pain and swelling (specify large vs. small joints, symmetry)
• Polymyalgia rheumatica symptoms: shoulder/hip girdle pain and stiffness
• Myositis symptoms: proximal muscle weakness, myalgia, dysphagia, dysarthria, dysphonia 3
• Temporal arteritis symptoms: headache, visual disturbances 2
• Sicca symptoms (dry eyes, dry mouth) 9

Endocrine 5:

• Fatigue severity
• Cold/heat intolerance
• Headache, visual changes (hypophysitis)
• Polyuria, polydipsia

Pulmonary 7:

• Dyspnea severity and exertional limitation
• Cough (productive vs. non-productive)
• Chest pain

Hepatic 5:

• Right upper quadrant pain
• Jaundice
• Dark urine

Renal 2:

• Urine output changes
• Peripheral edema

Neurologic 7:

• Sensory or motor neuropathy progression
• Headache severity
• Visual changes
• Weakness distribution

Cardiac (rare but life-threatening) 7, 5:

• Chest pain
• Palpitations
• Dyspnea on exertion

Monitoring Schedule

During Active Treatment

• Clinical assessment and symptom checklist: Every 2-3 weeks (with each ICI infusion)
• Laboratory monitoring: CBC, comprehensive metabolic panel, liver function, TSH prior to every dose 1, 6
• Creatinine monitoring: Before every ICI dose 2
• Technology-enabled patient-reported outcomes: Minimum 3 times weekly via smartphone application with automated alert thresholds 10

Post-Treatment Surveillance

• First year: Clinical and laboratory evaluation every 3 months 1
• After first year: Every 6 months 1
• Laboratory tests: CBC, renal function, electrolytes, glucose, liver function, TSH
• IrAEs can develop up to 1 year after ICI discontinuation 6

Predictive Biomarker Collection (Research Protocol)

Based on the 2022 Spanish multicenter prospective protocol 4:

Ordinary Blood Sampling Timepoints

• Baseline (before first ICI dose)
• Before each subsequent ICI cycle
• Week 12,24,36,48

Extraordinary Sampling

• At time of any irAE detection (regardless of grade)
• Store samples at -80°C until batch analysis

Autoantibody Panel Under Investigation

• Antinuclear antibodies
• Rheumatoid factor
• Antineutrophil cytoplasmic antibodies (ANCA)

The Spanish protocol estimates 25% irAE incidence and requires 294 patients to detect 90% sensitivity of this autoantibody panel 4.

Critical Pitfalls to Avoid

1. Do not dismiss mild creatinine elevations: Even changes <1.5× ULN can be clinically meaningful given baseline renal function 2

2. Myositis requires immediate action: Presence of bulbar symptoms (dysphagia, dysarthria, dysphonia), dyspnea, or myocarditis mandates immediate ICI discontinuation, high-dose corticosteroids, IVIG, and/or plasmapheresis 3

3. Distinguish disease progression from irAE: Always evaluate for tumor progression when new symptoms arise, as progression remains more common than irAEs 1

4. Pre-existing autoimmune disease is not an absolute contraindication: These patients can receive ICIs with close monitoring, though they have higher flare risk (>20% develop grade 3-4 irAEs) 2, 6, 2

5. Combination therapy (anti-CTLA-4 + anti-PD-1) dramatically increases toxicity: 54-59% grade 3-4 irAEs vs. 20-28% with ipilimumab alone or 22% with anti-PD-1 alone 5

Online Citation Access

The comprehensive baseline checklist is published in Table 2 of the 2016 Annals of Oncology collaborative position paper 1, freely accessible through PubMed (PMID: 27646559). The ASCO 2018 and 2021 guidelines 2, 11 provide detailed organ-specific diagnostic algorithms. The EULAR 2021 points to consider 3 specifically address rheumatologic irAEs. All major society guidelines (SITC, ESMO, NCCN, ASCO, EULAR) are available through their respective websites and provide complementary frameworks for multicenter study design.